<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03200000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>O14965</UniProt_ID>
  <Seq_Length>403</Seq_Length>
  <Molecule_Weight>45809</Molecule_Weight>
  <KEGG_ID>hsa:6790</KEGG_ID>
  <Orthology_ID>K11481</Orthology_ID>
  <EBI_ID>EBI-448680</EBI_ID>
  <Function_Summary>Mitotic serine/threonine kinases that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase activity. Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and stabilizating p53/TP53. Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity. Necessary for proper cilia disassembly prior to mitosis.</Function_Summary>
  <Catalytic_Mechanism>ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00069:Pkinase</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>64</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Aurora/IPL1-like kinase</Alias>
      <Alias>Serine/threonine-protein kinase aurora-A</Alias>
      <Alias>Serine/threonine-protein kinase 15</Alias>
      <Alias>ARK-1</Alias>
      <Alias>Breast tumor-amplified kinase</Alias>
      <Alias>HARK1</Alias>
      <Alias>Breast-tumor-amplified kinase</Alias>
      <Alias>Serine/threonine protein kinase 15</Alias>
      <Alias>Aurora-related kinase 1</Alias>
      <Alias>IPL1-related kinase</Alias>
      <Alias>Aurora/IPL1-related kinase 1</Alias>
      <Alias>Serine/threonine kinase 6</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + a protein serine = ADP + protein serine phosphate; ATP + a protein threonine = ADP + protein threonine phosphate; and ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein serine/threonine/tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004712</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.</Detail>
      <Keyword>Protein kinase binding</Keyword>
      <Ontology_ID>GO:0019901</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>57</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>11</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>104</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>373</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>31</Position>
      <Original>Phe</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>155</Position>
      <Original>Ser</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>174</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of mitosis.</Detail>
      <Keyword>Positive regulation of mitosis</Keyword>
      <Ontology_ID>GO:0045840</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a prolongation or process extending from a cell, e.g. a flagellum or axon.</Detail>
      <Keyword>Cell projection organization</Keyword>
      <Ontology_ID>GO:0030030</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.</Detail>
      <Keyword>Protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0046777</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.</Detail>
      <Keyword>Cell cycle</Keyword>
      <Ontology_ID>GO:0007049</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals in which a cell uses a phosphatidylinositol-mediated signaling to convert a signal into a response. Phosphatidylinositols include phosphatidylinositol (PtdIns) and its phosphorylated derivatives.</Detail>
      <Keyword>Phosphatidylinositol-mediated signaling</Keyword>
      <Ontology_ID>GO:0048015</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the centrosome cycle, the processes of centrosome duplication and separation.</Detail>
      <Keyword>Regulation of centrosome cycle</Keyword>
      <Ontology_ID>GO:0046605</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process resulting in the physical partitioning and separation of a cell into daughter cells.</Detail>
      <Keyword>Cell division</Keyword>
      <Ontology_ID>GO:0051301</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that affects the structure and integrity of a protein by altering the likelihood of its degradation or aggregation.</Detail>
      <Keyword>Regulation of protein stability</Keyword>
      <Ontology_ID>GO:0031647</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the spindle, the array of microtubules and associated molecules that forms between opposite poles of a eukaryotic cell during DNA segregation and serves to move the duplicated chromosomes apart.</Detail>
      <Keyword>Spindle organization</Keyword>
      <Ontology_ID>GO:0007051</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by the anaphase-promoting complex, and mediated by the proteasome.</Detail>
      <Keyword>Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process</Keyword>
      <Ontology_ID>GO:0031145</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cell cycle process comprising the steps by which the nucleus of a eukaryotic cell divides; the process involves condensation of chromosomal DNA into a highly compacted form. Canonically, mitosis produces two daughter nuclei whose chromosome complement is identical to that of the mother cell.</Detail>
      <Keyword>Mitosis</Keyword>
      <Ontology_ID>GO:0007067</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>288</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>342</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>83</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>369</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>53</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>51</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>287</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>41</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRVPLQAQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPEEELASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS</Protein_Seq>
    <DNA_Seq>ATGGACCGATCTAAAGAAAACTGCATTTCAGGACCTGTTAAGGCTACAGCTCCAGTTGGAGGTCCAAAACGTGTTCTCGTGACTCAGCAATTTCCTTGTCAGAATCCATTACCTGTAAATAGTGGCCAGGCTCAGCGGGTCTTGTGTCCTTCAAATTCTTCCCAGCGCATTCCTTTGCAAGCACAAAAGCTTGTCTCCAGTCACAAGCCGGTTCAGAATCAGAAGCAGAAGCAATTGCAGGCAACCAGTGTACCTCATCCTGTCTCCAGGCCACTGAATAACACCCAAAAGAGCAAGCAGCCCCTGCCATCGGCACCTGAAAATAATCCTGAGGAGGAACTGGCATCAAAACAGAAAAATGAAGAATCAAAAAAGAGGCAGTGGGCTTTGGAAGACTTTGAAATTGGTCGCCCTCTGGGTAAAGGAAAGTTTGGTAATGTTTATTTGGCAAGAGAAAAGCAAAGCAAGTTTATTCTGGCTCTTAAAGTGTTATTTAAAGCTCAGCTGGAGAAAGCCGGAGTGGAGCATCAGCTCAGAAGAGAAGTAGAAATACAGTCCCACCTTCGGCATCCTAATATTCTTAGACTGTATGGTTATTTCCATGATGCTACCAGAGTCTACCTAATTCTGGAATATGCACCACTTGGAACAGTTTATAGAGAACTTCAGAAACTTTCAAAGTTTGATGAGCAGAGAACTGCTACTTATATAACAGAATTGGCAAATGCCCTGTCTTACTGCCATTCGAAGAGAGTTATTCATAGAGACATTAAGCCAGAGAACTTACTTCTTGGATCAGCTGGAGAGCTTAAAATTGCAGATTTTGGGTGGTCAGTACATGCTCCATCTTCCAGGAGGACCACTCTCTGTGGCACCCTGGACTACCTGCCCCCTGAAATGATTGAAGGTCGGATGCATGATGAGAAGGTGGATCTCTGGAGCCTTGGAGTTCTTTGCTATGAATTTTTAGTTGGGAAGCCTCCTTTTGAGGCAAACACATACCAAGAGACCTACAAAAGAATATCACGGGTTGAATTCACATTCCCTGACTTTGTAACAGAGGGAGCCAGGGACCTCATTTCAAGACTGTTGAAGCATAATCCCAGCCAGAGGCCAATGCTCAGAGAAGTACTTGAACACCCCTGGATCACAGCAAATTCATCAAAACCATCAAATTGCCAAAACAAAGAATCAGCTAGCAAACAGTCTTAG</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Testis</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Thymus</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Spleen</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Cancer cell lines</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Centrosome</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Spindle pole</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>AURKA</Gene_Name>
    <Gene_Alias>AIK; AIRK1; ARK1; AURA; AYK1; BTAK; IAK1; STK15; STK6</Gene_Alias>
    <Gene_ID>6790</Gene_ID>
    <Genbank_ACCN>NM_003600</Genbank_ACCN>
    <Protein_ACCN>NP_003591</Protein_ACCN>
    <HGNC_ID>11393</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/6790</Gene_URL>
    <UCSC_ID>uc002xxd.1</UCSC_ID>
    <EMBL_ID>ENSG00000087586</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q9NWT8</Uniprot_ID>
      <Gene_Name>AURKAIP1</Gene_Name>
      <EBI_ID>EBI-448665</EBI_ID>
      <PPI_EBI_URL>EBI-448680,EBI-448665</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8VDQ8</Uniprot_ID>
      <Gene_Name>Sirt2</Gene_Name>
      <EBI_ID>EBI-911012</EBI_ID>
      <PPI_EBI_URL>EBI-448680,EBI-911012</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P04198</Uniprot_ID>
      <Gene_Name>MYCN</Gene_Name>
      <EBI_ID>EBI-878369</EBI_ID>
      <PPI_EBI_URL>EBI-448680,EBI-878369</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Neuroblastoma, Susceptibility</Disease_Name>
      <Disease_Detail>Neuroblastoma</Disease_Detail>
      <Disease_DB>NRB002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuroblastoma_susceptibility?search=AURKA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Laryngeal Carcinoma</Disease_Name>
      <Disease_Detail>Laryngeal Carcinoma</Disease_Detail>
      <Disease_DB>LRY016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/laryngeal_carcinoma?search=AURKA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colonic Benign Neoplasm</Disease_Name>
      <Disease_Detail>Colon Cancer</Disease_Detail>
      <Disease_DB>CLN045</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colonic_benign_neoplasm?search=AURKA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neuroblastoma</Disease_Name>
      <Disease_Detail>Neuroblastoma</Disease_Detail>
      <Disease_DB>NRB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuroblastoma?search=AURKA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Laryngeal Squamous Cell Carcinoma</Disease_Name>
      <Disease_Detail>Laryngeal Squamous Cell Carcinoma</Disease_Detail>
      <Disease_DB>LRY018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/laryngeal_squamous_cell_carcinoma?search=AURKA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atypical Teratoid Rhabdoid Tumor</Disease_Name>
      <Disease_Detail>Atypical Teratoid Rhabdoid Tumor</Disease_Detail>
      <Disease_DB>ATY005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atypical_teratoid_rhabdoid_tumor?search=AURKA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colorectal Cancer</Disease_Name>
      <Disease_Detail>Colorectal Cancer</Disease_Detail>
      <Disease_DB>CLR023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colorectal_cancer?search=AURKA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=AURKA#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>AURORA-A INHIBITOR STRUCTURE</PDB_Title>
      <PDB_ID>2WTV</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2WTV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-{[9-CHLORO-7-(2,6-DIFLUOROPHENYL)-5H-PYRIMIDO[5,4- D][2]BENZAZEPIN-2
-YL]AMINO}BENZOIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design.</PubMed_Title>
      <Author>Dodson CA, et al.</Author>
      <Journal>Biochem J. 2010 Mar 15;427(1):19-28.</Journal>
      <PubMed_ID>20067443</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR</PDB_Title>
      <PDB_ID>2W1G</PDB_ID>
      <Resolution>2.71</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2W1G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL- 3-YL}-6-(MORPHOLIN-4-IUM-4
-YLMETHYL)-1H-3,1- BENZIMIDAZOL-3-IUM</Ligand_Name>
      <PubMed_Title>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.</PubMed_Title>
      <Author>Howard S, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 379-388</Journal>
      <PubMed_ID>19143567</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR</PDB_Title>
      <PDB_ID>2W1D</PDB_ID>
      <Resolution>2.97</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2W1D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-(1H-pyrazol-3-yl)-1H-benzimidazole</Ligand_Name>
      <PubMed_Title>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.</PubMed_Title>
      <Author>Howard S, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 379-388</Journal>
      <PubMed_ID>19143567</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP</PDB_Title>
      <PDB_ID>2C6D</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2C6D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER</Ligand_Name>
      <PubMed_Title>SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.</PubMed_Title>
      <Author>Heron NM, et al.</Author>
      <Journal>(2006) Bioorg.Med.Chem.Lett. 16: 1320</Journal>
      <PubMed_ID>16337122</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR</PDB_Title>
      <PDB_ID>2W1F</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2W1F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4- YL]BENZAMIDE</Ligand_Name>
      <PubMed_Title>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.</PubMed_Title>
      <Author>Howard S, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 379-388</Journal>
      <PubMed_ID>19143567</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF AURORA-2, AN ONCOGENIC SERINE-THREONINE KINASE</PDB_Title>
      <PDB_ID>1MUO</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=1MUO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE</Ligand_Name>
      <PubMed_Title>Crystal structure of aurora-2, an oncogenic serine/threonine kinase.</PubMed_Title>
      <Author>Cheetham GM, et al.</Author>
      <Journal>(2002) J.Biol.Chem. 277: 42419-42422</Journal>
      <PubMed_ID>12237287</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Aurora A inhibitor complex</PDB_Title>
      <PDB_ID>3H10</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3H10</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>9-chloro-7-(2,6-difluorophenyl)-N-{4-[(4- methylpiperazin-1-yl)carbonyl]phenyl}
-5H- pyrimido[5,4-d][2]benzazepin-2-amine</Ligand_Name>
      <PubMed_Title>A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.</PubMed_Title>
      <Author>Aliagas-Martin I, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 3300-3307</Journal>
      <PubMed_ID>19402633</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A</PDB_Title>
      <PDB_ID>1OL6</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=1OL6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-TRIPHOSPHATE</Ligand_Name>
      <PubMed_Title>Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.</PubMed_Title>
      <Author>Bayliss R, et al.</Author>
      <Journal>(2003) Mol.Cell 12: 851</Journal>
      <PubMed_ID>14580337</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR</PDB_Title>
      <PDB_ID>2W1C</PDB_ID>
      <Resolution>3.24</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2W1C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-{[2-(4-{[(4-FLUOROPHENYL)CARBONYL]AMINO}- 1H-PYRAZOL-3-YL)-1H-BENZIMIDAZOL-6
-YL]METHYL}MORPHOLIN- 4-IUM</Ligand_Name>
      <PubMed_Title>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.</PubMed_Title>
      <Author>Howard S, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 379-388</Journal>
      <PubMed_ID>19143567</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF S155R AURORA-A SOMATIC MUTANT</PDB_Title>
      <PDB_ID>2WQE</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2WQE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-DIPHOSPHATE</Ligand_Name>
      <PubMed_Title>A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2.</PubMed_Title>
      <Author>Bibby RA, et al.</Author>
      <Journal>(2009) J.Biol.Chem. 284: 33177-33184</Journal>
      <PubMed_ID>19801554</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF AURORA-A 122-403, PHOSPHORYLATED ON THR287, THR288 AND BOUND TO TPX2 1-43</PDB_Title>
      <PDB_ID>1OL5</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=1OL5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-DIPHOSPHATE</Ligand_Name>
      <PubMed_Title>Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.</PubMed_Title>
      <Author>Bayliss R, et al.</Author>
      <Journal>(2003) Mol.Cell 12: 851</Journal>
      <PubMed_ID>14580337</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Aurora A in complex with a bisanilinopyrimidine</PDB_Title>
      <PDB_ID>3H0Y</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3H0Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-chloro-N-[4-({5-fluoro-2-[(4-hydroxyphenyl)amino]pyrimidin- 4
-yl}amino)phenyl]benzamide</Ligand_Name>
      <PubMed_Title>A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.</PubMed_Title>
      <Author>Aliagas-Martin I, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 3300-3307</Journal>
      <PubMed_ID>19402633</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287, THR288</PDB_Title>
      <PDB_ID>1OL7</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=1OL7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-DIPHOSPHATE</Ligand_Name>
      <PubMed_Title>Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.</PubMed_Title>
      <Author>Bayliss R, et al.</Author>
      <Journal>(2003) Mol.Cell 12: 851</Journal>
      <PubMed_ID>14580337</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Aurora-A Protein Kinase</PDB_Title>
      <PDB_ID>1MQ4</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=1MQ4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-DIPHOSPHATE</Ligand_Name>
      <PubMed_Title>Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography.</PubMed_Title>
      <Author>Nowakowski J, et al.</Author>
      <Journal>(2002) Structure 10: 1659-1667</Journal>
      <PubMed_ID>12467573</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Aurora A in complex with a bisanilinopyrimidine</PDB_Title>
      <PDB_ID>3H0Z</PDB_ID>
      <Resolution>2.92</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3H0Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-{[2-({4-[2-(4-acetylpiperazin-1-yl)-2-oxoethyl]phenyl}amino)- 5
-fluoropyrimidin-4-yl]amino}-N-(2-chlorophenyl)benzamide</Ligand_Name>
      <PubMed_Title>A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.</PubMed_Title>
      <Author>Aliagas-Martin I, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 3300-3307</Journal>
      <PubMed_ID>19402633</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR</PDB_Title>
      <PDB_ID>2C6E</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2C6E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-{5-[(7-{[(2S)-2-HYDROXY-3-PIPERIDIN-1-YLPROPYL]OXY}- 6-METHOXYQUINAZOLIN-4
-YL)AMINO]PYRIMIDIN- 2-YL}BENZAMIDE</Ligand_Name>
      <PubMed_Title>SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.</PubMed_Title>
      <Author>Heron NM, et al.</Author>
      <Journal>(2006) Bioorg.Med.Chem.Lett. 16: 1320</Journal>
      <PubMed_ID>16337122</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358</PDB_Title>
      <PDB_ID>2J50</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2J50</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[(3E)-5-[(2R)-2-METHOXY-2-PHENYLACETYL]PYRROLO[3,4- C]PYRAZOL-3(5H)-YLIDENE]-4
-(4-METHYLPIPERAZIN- 1-YL)BENZAMIDE</Ligand_Name>
      <PubMed_Title>1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.</PubMed_Title>
      <Author>Fancelli D, et al.</Author>
      <Journal>(2006) J.Med.Chem. 49: 7247</Journal>
      <PubMed_ID>17125279</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)</PDB_Title>
      <PDB_ID>2WTW</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2WTW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-{[9-CHLORO-7-(2,6-DIFLUOROPHENYL)-5H-PYRIMIDO[5,4- D][2]BENZAZEPIN-2
-YL]AMINO}BENZOIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design.</PubMed_Title>
      <Author>Dodson CA, et al.</Author>
      <Journal>Biochem J. 2010 Mar 15;427(1):19-28.</Journal>
      <PubMed_ID>20067443</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Aurora-A kinase complexed with AMPPNP</PDB_Title>
      <PDB_ID>2DWB</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2DWB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER</Ligand_Name>
      <PubMed_Title>Aurora-A kinase complexed with AMPPNP</PubMed_Title>
      <Author>Kukimoto-Niino M, et al.</Author>
      <Journal>To be Published</Journal>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626</PDB_Title>
      <PDB_ID>2J4Z</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2J4Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)- 1,5-DIHYDROPYRROLO[3,4
-C]PYRAZOL-3-YL]BENZAMIDE</Ligand_Name>
      <PubMed_Title>1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.</PubMed_Title>
      <Author>Fancelli D, et al.</Author>
      <Journal>(2006) J.Med.Chem. 49: 7247-7251</Journal>
      <PubMed_ID>17125279</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of AuroraA with pyridyl-pyrimidine urea inhibitor</PDB_Title>
      <PDB_ID>3EFW</PDB_ID>
      <Resolution>2.29</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3EFW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-[3-methyl-4-({3-[2-(methylamino)pyrimidin- 4-yl]pyridin-2-yl}oxy)phenyl]-3-[3-
(trifluoromethyl)phenyl]urea</Ligand_Name>
      <PubMed_Title>Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.</PubMed_Title>
      <Author>Cee VJ, et al.</Author>
      <Journal>(2008) Bioorg.Med.Chem.Lett.</Journal>
      <PubMed_ID>19062275</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of aurora A in complex with TPX2 and compound 10</PDB_Title>
      <PDB_ID>3HA6</PDB_ID>
      <Resolution>2.36</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3HA6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N~2~-(3,4-dimethoxyphenyl)-N~4~-[2-(2-fluorophenyl)ethyl]- N~6~-quinolin-6-yl
-1,3,5-triazine-2,4,6-triamine</Ligand_Name>
      <PubMed_Title>Design, Synthesis, and Selection of DNA Encoded Small Molecule Libraries</PubMed_Title>
      <Author>Clark MA, et al.</Author>
      <Journal>TO BE PUBLISHED</Journal>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR</PDB_Title>
      <PDB_ID>2W1E</PDB_ID>
      <Resolution>2.93</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2W1E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[(2-{4-[(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL- 3-YL}-1H-BENZIMIDAZOL-5
-YL)METHYL]MORPHOLIN- 4-IUM</Ligand_Name>
      <PubMed_Title>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.</PubMed_Title>
      <Author>Howard S, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 379-388</Journal>
      <PubMed_ID>19143567</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Aurora-A in complex with a pentacyclic inhibitor</PDB_Title>
      <PDB_ID>3COH</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3COH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta
[1,2- b]pyrrolo[2,3-f]indol-9(1H)-one</Ligand_Name>
      <PubMed_Title>A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.</PubMed_Title>
      <Author>Rawson TE, et al.</Author>
      <Journal>(2008) J.Med.Chem. 51: 4465-4475</Journal>
      <PubMed_ID>18630890</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural Basis for the Inhibition of Aurora A Kinase by a Novel Class of High Affinity Disubstituted Pyrimidine Inhibitors</PDB_Title>
      <PDB_ID>2NP8</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2NP8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN- 2
-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE</Ligand_Name>
      <PubMed_Title>Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors.</PubMed_Title>
      <Author>Tari LW, et al.</Author>
      <Journal>(2007) Bioorg.Med.Chem.Lett. 17: 688-691</Journal>
      <PubMed_ID>17157005</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure-based drug design of novel Aurora kinase A inhibitors: Structure basis for potency and specificity</PDB_Title>
      <PDB_ID>3FDN</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3FDN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[3-(acetylamino)phenyl]-5-{(2E)-2-[(4-methoxyphenyl)methylidene]hydrazino}- 3
-methyl-1H-pyrazole-4-carboxamide</Ligand_Name>
      <PubMed_Title>Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.</PubMed_Title>
      <Author>Coumar MS, et al.</Author>
      <Journal>(2009) J.Med.Chem. 52: 1050-1062</Journal>
      <PubMed_ID>19140666</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Aurora2 kinase in complex with a GSK3beta inhibitor</PDB_Title>
      <PDB_ID>3LAU</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=3LAU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[6-(4-hydroxyphenyl)-1H-indazol-3-yl]butanamide</Ligand_Name>
      <PubMed_Title>Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.</PubMed_Title>
      <Author>Lesuisse D, et al.</Author>
      <Journal>(2010) Bioorg.Med.Chem.Lett. 20: 1985-1989</Journal>
      <PubMed_ID>20167481</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Aurora A in complex with VX-680 and TPX2</PDB_Title>
      <PDB_ID>3E5A</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E5A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>CYCLOPROPANECARBOXYLIC ACID {4-[4-(4-METHYL- PIPERAZIN-1-YL)-6-(5-METHYL-2H
-PYRAZOL-3- YLAMINO)-PYRIMIDIN-2-YLSULFANYL]-PHENYL}- AMIDE</Ligand_Name>
      <PubMed_Title>Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.</PubMed_Title>
      <Author>Zhao B, et al.</Author>
      <Journal>Protein Sci.2008 Oct;17(10):1791-7. Epub  2008 Jul 28.</Journal>
      <PubMed_ID>18662907</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AURORA-2 T287D T288D COMPLEXED WITH PHA-680632</PDB_Title>
      <PDB_ID>2BMC</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=2BMC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(3E)-N-(2,6-DIETHYLPHENYL)-3-{[4-(4-METHYLPIPERAZIN- 1-YL)BENZOYL]IMINO}PYRROLO
[3,4-C]PYRAZOLE- 5(3H)-CARBOXAMIDE</Ligand_Name>
      <PubMed_Title>Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.</PubMed_Title>
      <Author>Fancelli D, et al.</Author>
      <Journal>(2005) J.Med.Chem. 48: 3080</Journal>
      <PubMed_ID>15828847</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04114</Pathway_ID>
      <Pathway_Title>Oocyte meiosis</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.daa.b.b.df.html</SCOP_URL>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/domain/1ol6A01</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,288,Thr</Site_Detail>
      <Site_Reference>Satinover DL, et al. Proc.Natl.Acad.Sci U S A. 2004,101(23):8625-8630.</Site_Reference>
      <Site_Type>Protein-induced</Site_Type>
      <PubMed_ID>15173575</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.11.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/11/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD03200001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200022</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200023</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200024</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200025</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200027</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200028</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200029</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200030</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200031</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200032</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200033</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200034</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200035</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200036</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200037</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200038</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200039</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200040</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200041</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200042</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200043</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200044</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200046</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200048</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200049</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200050</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200051</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200052</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200053</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200054</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200055</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200056</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200057</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200058</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200059</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200060</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200061</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200062</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200063</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200064</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03200065</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>